An observational study in Pneumonia, Bloodstream Infection and Urinary Tract Infections, sponsored by Hospital Universitario Virgen Macarena. Enrolling by invitation at 1 site in Spain. Per ClinicalTrials.gov, last updated 2023-05-30.
Sponsored by Hospital Universitario Virgen Macarena · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Pneumonia with a site in Spain — 12 open to participants now, 13 under way, 4 of them phase 3. Pneumonia · Spain.
Among the 79 studies in Pneumonia with a site in Spain, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 68th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →12 of the 79 studies in Pneumonia with a site in Spain are open now. Recruiting first, the newest first:
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Iconic Solutions By Murcia SL · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 16 more countries
Ages 12+
PEACHES BIOTECH · Sites in Spain
Ages 18+
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 18–100
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 33 · Phase 4 6
First in 2000; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 174 across the 67 interventional studies, 763 across the 12 observational. Of the 56 that completed or were terminated, 18 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 79 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario Virgen Macarena is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Hospital Universitario Virgen Macarena has 1 study filed under Pneumonia — fewer than ten, so there is no comparison to draw.
6 of the studies in Pneumonia with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
| NCT05452941PfizerA Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting | 2027-06-04 |
| NCT07883902Santiago Lopez GilExpanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 79 studies in Pneumonia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and urinary tract infections, caused by target drug-resistant pathogens, in high income countries.
The main question[s] it aims to answer are:
Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows: 1. P. aeruginosa, carbapenems resistant: BSI 2. A. baumannii, carbapenems resistant: BSI 3. E. coli, 3rd generation cephalosporins resistant: BSI and UTI 4. K. pneumoniae, 3rd generation cephalosporins resistant: BSI 5. K. pneumoniae, carbapenems resistant: BSI 6. S. aureus, methicillin resistant: BSI, pneumonia, SSI and SSTI 7. E faecium, vancomycin resistant: BSI 8. Enterobacterales, 3rd generation cephalosporins resistant: BSI
Other: Pathogen resistant phenotype
Individuals of all ages with the target pathogen, susceptible phenotype, and infection site combinations as follows: 1. P. aeruginosa, carbapenems susceptible: BSI 2. A. baumannii, carbapenems susceptible: BSI 3. E. coli, 3rd generation cephalosporins susceptible: BSI and UTI 4. K. pneumoniae, 3rd generation cephalosporins susceptible: BSI 5. K. pneumoniae, carbapenems susceptible: BSI 6. S. aureus, methicillin susceptible: BSI, pneumonia, SSI and SSTI 7. E faecium, vancomycin susceptible: BSI 8. Enterobacterales, 3rd generation cephalosporins susceptible: BSI
Other: Pathogen resistant phenotype
Individuals of all ages without the infection under study
Drug resistant phenotype of the target pathogen under study
Mortality
Death any time after infection, during the follow-up time of the original study.
Time frame: Through study completion, an average of 1 year
Number of participants with ICU admission
Need for an admission in ICU setting for more than 24 hours after infection onset.
Time frame: Through study completion, an average of 1 year
Number of participants with clinical cure
Absence of symptoms after completion of an antibiotic treatment course.
Time frame: Through study completion, an average of 1 year
Number of participants with microbiological cure
No isolation of the causal microorganisms after completion of an antibiotic treatment course.
Time frame: Through study completion, an average of 1 year
Number of participants with recurrence of infection
Infection with the same organism after more than two weeks of the initial infection.
Time frame: Through study completion, an average of 1 year
Number of participants with superinfection
Other infections different from the one under assessment.
Time frame: Through study completion, an average of 1 year
Number of participants with cognitive impairment / disability
Impairment is any temporal or permanent loss of function; disability is a restriction or inability to perform a normal activity resulting from an impairment. Assessed using Center for Epidemiologic Studies Depression Scale (CES-D), Mini-Mental State Examination (MMSE) or Trail Making Test (TMT).
Time frame: Through study completion, an average of 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Jun 2023, 8 months after the start.
Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 8 months is below that.
Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Virgen Macarena